,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,4275 Executive Square,Suite 300,La Jolla,CA,92037,United States,858 373 1500,858 404 0048,https://www.medicinova.com,Biotechnology,Healthcare,"MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.",13,"{'maxAge': 1, 'name': 'Dr. Yuichi  Iwaki M.D., Ph.D.', 'age': 72, 'title': 'Co-Founder, Pres, CEO & Exec. Director', 'yearBorn': 1950, 'fiscalYear': 2022, 'totalPay': 933046, 'exercisedValue': 0, 'unexercisedValue': 0}",9,10,7,5,8,1693526400,1672444800,86400,4,2.23,2.252,2.04,2.252,2.23,2.252,2.04,2.252,0.0,0.935338,-6.375,53049,53049,19219,17490,17490,1.87,2.25,1000,800,100054248,1.89,2.73,2.3716,2.2914,0.0,0.0,USD,47899032,0.0,42072360,49046200,369453,369246,1690761600,1693440000,0.0075,0.029830001,0.22600001,20.61,0.009,1.329,1.5349886,1672444800,1703980800,1688083200,-12442992,-0.24,-0.32,-0.4,1:10,1162252800,-3.581,NGM,EQUITY,MNOV,MNOV,"MediciNova, Inc.","MediciNova, Inc.",1165588200,America/New_York,EDT,-14400000,2.04,26.0,6.0,16.0,16.0,2.0,buy,2,52876272,1.078,-13374085,720962,18.742,18.971,1.106,-0.11163,-0.17552,-8318565,-12287624,0.0,0.0,0.0,USD,
1,4275 Executive Square,Suite 300,La Jolla,CA,92037,United States,858 373 1500,858 404 0048,https://www.medicinova.com,Biotechnology,Healthcare,"MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.",13,"{'maxAge': 1, 'name': 'Dr. Kazuko  Matsuda M.D., M.P.H., MPH, Ph.D.', 'age': 56, 'title': 'Chief Medical Officer & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 653654, 'exercisedValue': 0, 'unexercisedValue': 0}",9,10,7,5,8,1693526400,1672444800,86400,4,2.23,2.252,2.04,2.252,2.23,2.252,2.04,2.252,0.0,0.935338,-6.375,53049,53049,19219,17490,17490,1.87,2.25,1000,800,100054248,1.89,2.73,2.3716,2.2914,0.0,0.0,USD,47899032,0.0,42072360,49046200,369453,369246,1690761600,1693440000,0.0075,0.029830001,0.22600001,20.61,0.009,1.329,1.5349886,1672444800,1703980800,1688083200,-12442992,-0.24,-0.32,-0.4,1:10,1162252800,-3.581,NGM,EQUITY,MNOV,MNOV,"MediciNova, Inc.","MediciNova, Inc.",1165588200,America/New_York,EDT,-14400000,2.04,26.0,6.0,16.0,16.0,2.0,buy,2,52876272,1.078,-13374085,720962,18.742,18.971,1.106,-0.11163,-0.17552,-8318565,-12287624,0.0,0.0,0.0,USD,
2,4275 Executive Square,Suite 300,La Jolla,CA,92037,United States,858 373 1500,858 404 0048,https://www.medicinova.com,Biotechnology,Healthcare,"MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.",13,"{'maxAge': 1, 'name': 'Mr. Jason J. Kruger CPA', 'age': 45, 'title': 'CFO & Principal Financial Officer', 'yearBorn': 1977, 'exercisedValue': 0, 'unexercisedValue': 0}",9,10,7,5,8,1693526400,1672444800,86400,4,2.23,2.252,2.04,2.252,2.23,2.252,2.04,2.252,0.0,0.935338,-6.375,53049,53049,19219,17490,17490,1.87,2.25,1000,800,100054248,1.89,2.73,2.3716,2.2914,0.0,0.0,USD,47899032,0.0,42072360,49046200,369453,369246,1690761600,1693440000,0.0075,0.029830001,0.22600001,20.61,0.009,1.329,1.5349886,1672444800,1703980800,1688083200,-12442992,-0.24,-0.32,-0.4,1:10,1162252800,-3.581,NGM,EQUITY,MNOV,MNOV,"MediciNova, Inc.","MediciNova, Inc.",1165588200,America/New_York,EDT,-14400000,2.04,26.0,6.0,16.0,16.0,2.0,buy,2,52876272,1.078,-13374085,720962,18.742,18.971,1.106,-0.11163,-0.17552,-8318565,-12287624,0.0,0.0,0.0,USD,
3,4275 Executive Square,Suite 300,La Jolla,CA,92037,United States,858 373 1500,858 404 0048,https://www.medicinova.com,Biotechnology,Healthcare,"MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.",13,"{'maxAge': 1, 'name': 'Dr. David H. Crean M.B.A., Ph.D.', 'age': 57, 'title': 'Chief Bus. Officer', 'yearBorn': 1965, 'exercisedValue': 0, 'unexercisedValue': 0}",9,10,7,5,8,1693526400,1672444800,86400,4,2.23,2.252,2.04,2.252,2.23,2.252,2.04,2.252,0.0,0.935338,-6.375,53049,53049,19219,17490,17490,1.87,2.25,1000,800,100054248,1.89,2.73,2.3716,2.2914,0.0,0.0,USD,47899032,0.0,42072360,49046200,369453,369246,1690761600,1693440000,0.0075,0.029830001,0.22600001,20.61,0.009,1.329,1.5349886,1672444800,1703980800,1688083200,-12442992,-0.24,-0.32,-0.4,1:10,1162252800,-3.581,NGM,EQUITY,MNOV,MNOV,"MediciNova, Inc.","MediciNova, Inc.",1165588200,America/New_York,EDT,-14400000,2.04,26.0,6.0,16.0,16.0,2.0,buy,2,52876272,1.078,-13374085,720962,18.742,18.971,1.106,-0.11163,-0.17552,-8318565,-12287624,0.0,0.0,0.0,USD,
4,4275 Executive Square,Suite 300,La Jolla,CA,92037,United States,858 373 1500,858 404 0048,https://www.medicinova.com,Biotechnology,Healthcare,"MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.",13,"{'maxAge': 1, 'name': ""Mr. John  O'Neil CPA"", 'title': 'Controller', 'exercisedValue': 0, 'unexercisedValue': 0}",9,10,7,5,8,1693526400,1672444800,86400,4,2.23,2.252,2.04,2.252,2.23,2.252,2.04,2.252,0.0,0.935338,-6.375,53049,53049,19219,17490,17490,1.87,2.25,1000,800,100054248,1.89,2.73,2.3716,2.2914,0.0,0.0,USD,47899032,0.0,42072360,49046200,369453,369246,1690761600,1693440000,0.0075,0.029830001,0.22600001,20.61,0.009,1.329,1.5349886,1672444800,1703980800,1688083200,-12442992,-0.24,-0.32,-0.4,1:10,1162252800,-3.581,NGM,EQUITY,MNOV,MNOV,"MediciNova, Inc.","MediciNova, Inc.",1165588200,America/New_York,EDT,-14400000,2.04,26.0,6.0,16.0,16.0,2.0,buy,2,52876272,1.078,-13374085,720962,18.742,18.971,1.106,-0.11163,-0.17552,-8318565,-12287624,0.0,0.0,0.0,USD,
